This information was published on 2026-08-11T16:33:02 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2684094 |
| (220) |
06 Aug 2026
|
| (300) |
US, 24 Feb 2026, 99668592
|
| (511) (510) |
Class 5
Pharmaceutical preparations and drugs for the treatment, control, prevention, maintenance, and management of inflammatory and respiratory diseases and symptoms in humans; anti-inflammatory and immunomodulatory pharmaceutical compositions; medications for respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, cystic fibrosis, pneumonia, allergic rhinitis, Idiopathic Pulmonary Fibrosis (IPF), bronchiectasis, chronic cough and other pulmonary disorders; pharmaceutical compositions in the form of tablets, capsules, liquids, aerosols, inhalers, creams, ointments, gels, and injectables; fixed-dose combination pharmaceutical preparations for inflammatory and respiratory diseases and symptoms in humans; combination pharmaceutical preparations comprising two or more active ingredients for inflammatory and respiratory diseases and symptoms in humans; pharmaceutical preparations for use in combination therapy for inflammatory and respiratory diseases and symptoms in humans Class 42 Research, development, and formulation being research and development of pharmaceuticals for inflammatory and respiratory diseases; pharmaceutical formulation in the nature of pharmaceutical research and development services in the field of inflammatory and respiratory diseases Class 44 Provision of medical information and medical advice relating to inflammatory and respiratory diseases; medical services relating to inflammatory and respiratory diseases |
| (540) | AIRNEXIS |
| (550) | Word |
| (730) |
AirNexis Therapeutics, Inc.
|
| (750) |
AJ Park
|
Find out more about publications on the About page.